{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:35:11Z","timestamp":1760056511802,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ccl.2019.07.013","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T16:09:30Z","timestamp":1570118970000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias"],"prefix":"10.1016","volume":"37","author":[{"given":"Kevin M.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Evangelisti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ccl.2019.07.013_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"38","key":"10.1016\/j.ccl.2019.07.013_bib2","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.013_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.013_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.013_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/anec.12036","article-title":"Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis","volume":"18","author":"Mussinelli","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.013_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"19","key":"10.1016\/j.ccl.2019.07.013_bib7","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.013_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jacc.2012.06.007","article-title":"Longitudinal strain imaging in light-chain cardiac amyloidosis: can it help to refine the approach to treatment?","volume":"60","author":"Quarta","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.013_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.013_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2019.07.013_bib12","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light chain (AL) amyloidosis by whole body (18)F-florbetapir PET\/CT","author":"Ehman","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.013_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.013_bib14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study","volume":"57","author":"Law","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.013_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","article-title":"18)F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition","volume":"8","author":"Baratto","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.013_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0735-1097(92)90049-S","article-title":"Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center","volume":"19","author":"Deckers","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ccl.2019.07.013_bib18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","article-title":"Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period","volume":"118","author":"Holzmann","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.013_bib19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archinte.1988.00380040169024","article-title":"Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain)","volume":"148","author":"Gertz","year":"1988","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib20","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.013_bib21","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis","volume":"92","author":"Geller","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2012.108","article-title":"Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.013_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ccl.2019.07.013_bib24","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.013_bib25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.013_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.013_bib28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jacc.2018.10.043","volume":"74","author":"Kusumoto","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.013_bib30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.013_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.013_bib32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.013_bib33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","article-title":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","volume":"34","author":"Davis","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.013_bib34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.013_bib35","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ccl.2019.07.013_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.013_bib37","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.013_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.13805","article-title":"Recent advances in the management of AL amyloidosis","volume":"172","author":"Kastritis","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccl.2019.07.013_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2017.06.011","article-title":"Novel pharmacotherapies for cardiac amyloidosis","volume":"180","author":"Alexander","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.013_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.12136","article-title":"Bortezomib in the treatment of AL amyloidosis: targeted therapy?","volume":"92","author":"Sitia","year":"2007","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.ccl.2019.07.013_bib42","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.013_bib44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.ccl.2019.07.013_bib45","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ccl.2019.07.013_bib46","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.013_bib47","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.clinthera.2013.08.015","article-title":"Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.013_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European Collaborative Study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ccl.2019.07.013_bib49","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.013_bib52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.013_bib54","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.013_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.ccl.2019.07.013_bib59","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.013_bib61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.013_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.013_bib63","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.ccl.2019.07.013_bib64","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.013_bib65","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ccl.2019.07.013_bib66","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:51:15Z","timestamp":1760007075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865119300621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0733865119300621"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.013","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}